Your browser doesn't support javascript.
loading
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.
Morris, Katrina A; Golding, John F; Blesing, Claire; Evans, D Gareth; Ferner, Rosalie E; Foweraker, Karen; Halliday, Dorothy; Jena, Raj; McBain, Catherine; McCabe, Martin G; Swampillai, Angela; Warner, Nicola; Wilson, Shaun; Parry, Allyson; Afridi, Shazia K.
Afiliación
  • Morris KA; Nuffield Department of Neurosciences and NF2 Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Golding JF; University of New South Wales, Sydney, Australia.
  • Blesing C; University of Westminster, London, UK.
  • Evans DG; John Radcliffe Hospital, Oxford Cancer Centre, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ferner RE; Genomic Medicine, Institute of Human Development, MAHSC, University of Manchester, St Mary's Hospital, Manchester, UK.
  • Foweraker K; Department of Neurology, Neurofibromatosis Service, Guy's & St Thomas' Hospital, Great Maze Pond, London, SE1 9RT, UK.
  • Halliday D; Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Jena R; Department of Genetics and NF2 Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • McBain C; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • McCabe MG; The Christie NHS Foundation Trust, Manchester, UK.
  • Swampillai A; Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, University of Manchester, Manchester, UK.
  • Warner N; Department of Neurology, Neurofibromatosis Service, Guy's & St Thomas' Hospital, Great Maze Pond, London, SE1 9RT, UK.
  • Wilson S; John Radcliffe Hospital, Oxford Cancer Centre, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Parry A; Department of Paediatric Oncology, The West Wing, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Afridi SK; Nuffield Department of Neurosciences and NF2 Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
J Neurooncol ; 131(1): 117-124, 2017 01.
Article en En | MEDLINE | ID: mdl-27796735
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neurofibromatosis 2 / Bevacizumab / Antineoplásicos Inmunológicos / Insuficiencia Cardíaca / Hipertensión / Neurilemoma Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurooncol Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neurofibromatosis 2 / Bevacizumab / Antineoplásicos Inmunológicos / Insuficiencia Cardíaca / Hipertensión / Neurilemoma Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurooncol Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido